Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2001

01-12-2002 | Paper Report

bcl-2: a convergence point for multiple signal transduction pathways that influence cell survival?

Author: Julia MW Gee

Published in: Breast Cancer Research | Issue 1/2001

Login to get access

Excerpt

Members of the bcl-2 family of proteins, such as bcl-2 and mcl-1, have been implicated in controlling cell survival in many normal and neoplastic cells in a tissue-specific manner. Delineating those family members of relevance to breast cancer and manipulation of their regulatory signalling pathways is therapeutically attractive. The aim of this study, performed in MCF-7 human breast cancer cells, was to determine whether inhibition of protein tyrosine kinase, protein kinase C, phosphatidylinositol 3-kinase or mitogen-activated protein kinase kinase (MEK) signal transduction influences expression of bcl-2 or mcl-1, monitoring cytotoxicity in parallel. …
Literature
1.
Hu Y, Dragowska WH, Wallis A, Duronio V, Mayer L: Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of BCL-2 but not MCL-1 in MCF-7 human breast cancer. Breast Cancer Res Treat. 2001, 70: 11-20.CrossRefPubMed
Metadata
Title
bcl-2: a convergence point for multiple signal transduction pathways that influence cell survival?
Author
Julia MW Gee
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2002-74403

Other articles of this Issue 1/2001

Breast Cancer Research 1/2001 Go to the issue

Commentary

Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models

Commentary

E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?

Commentary

Mammographic breast density as a biomarker of effects of isoflavones on the female breast

Paper Report

Gene expression profiling

Review

The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer

Review

The role of bisphosphonates in breast cancer: Direct effects of bisphosphonates on breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits